Enter your keyword

Insights

Novo Nordisk Announces it will Release an Authorized Generic Version of its Insulin Products

On September 6th,  Novo Nordisk announced it would release an authorized a generic versions of NovoLog® and NovoLog® Mix at a 50% discount compared to the brand version. The FDA states that “The term ‘authorized generic’ drug is most commonly used to describe an approved brand name drug that is marketed without the brand name […]

Probable Human Carcinogen Found in Zantac (ranitidine)

On October 13th, 2019, the Food and Drug Administration(FDA) announced some ranitidine products, including some medications commonly known as the brand-name drug Zantac, contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. NDMA is classified as an agent that could cause cancer in humans. The FDA has been investigating NDMA and other nitrosamine impurities […]

Will the Rebate Bubble Burst?

Clients often ask about the future of rebates, which have been used by pharmacy benefits managers, health plans and plan sponsors to partially offset the cost of prescription drugs. In the past, rebates were viewed as a desirable financial component of the PBM pricing equation. Recently, however, rebates are viewed as a necessary evil. Rebates […]